|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Kura Oncology, Inc.
| | | Phone: | (617) 588-3760 | Year Established: | 2014 | Ticker: | KURA | Exchange: | NASDAQ | Main Contact: | Troy Wilson, Ph.D., J.D., President & CEO | | Other Contacts: | Blake Tomkinson, Ph.D., MBA, VP, Clinical Development Bridget Martell, M.A., M.D., VP, Clinical Development Annette North, Senior VP & General Counsel Pingda Ren, Ph.D., Senior VP, Chemistry and Pharmaceutical Sciences Antonio Gualberto, M.D., Ph.D., CMO Yi Liu, Ph.D., CSO & Co-Founder Marc Grasso, M.D., CFO & CBO John Farnam, COO
| | Company Description | Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. | |
|
|
|
|
|